Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Sponsor: Kite, A Gilead Company
A observational or N/A phase clinical study on Solid and Hematological Malignancies, this trial is ongoing. The trial is conducted by Kite, A Gilead Company and has accumulated 43 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
43 versions recorded-
Feb 2026 — Present [monthly]
Enrolling By Invitation
-
Nov 2025 — Feb 2026 [monthly]
Enrolling By Invitation
-
Oct 2025 — Nov 2025 [monthly]
Enrolling By Invitation
-
Sep 2025 — Oct 2025 [monthly]
Enrolling By Invitation
-
Jul 2025 — Sep 2025 [monthly]
Enrolling By Invitation
▶ Show 38 earlier versions
-
Mar 2025 — Jul 2025 [monthly]
Enrolling By Invitation
-
Feb 2025 — Mar 2025 [monthly]
Enrolling By Invitation
-
Jan 2025 — Feb 2025 [monthly]
Enrolling By Invitation
Phase: PHASE2 → None
-
Nov 2024 — Jan 2025 [monthly]
Enrolling By Invitation PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Enrolling By Invitation PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Enrolling By Invitation PHASE2
-
May 2024 — Jun 2024 [monthly]
Enrolling By Invitation PHASE2
-
Apr 2024 — May 2024 [monthly]
Enrolling By Invitation PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Enrolling By Invitation PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Enrolling By Invitation PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Enrolling By Invitation PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Enrolling By Invitation PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Enrolling By Invitation PHASE2
-
May 2023 — Jun 2023 [monthly]
Enrolling By Invitation PHASE2
-
Apr 2023 — May 2023 [monthly]
Enrolling By Invitation PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Enrolling By Invitation PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Enrolling By Invitation PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Enrolling By Invitation PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Enrolling By Invitation PHASE2
-
May 2022 — Jun 2022 [monthly]
Enrolling By Invitation PHASE2
-
Apr 2022 — May 2022 [monthly]
Enrolling By Invitation PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Enrolling By Invitation PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Enrolling By Invitation PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kite, A Gilead Company
For direct contact, visit the study record on ClinicalTrials.gov .